Home The History of Synthetic Biology Designing Synthetic Biotics Pipeline Our People Leadership Board of Directors Founders and Advisors Investors + Media Company Overview News News Releases In the News Events & Presentations Events Presentations Publications Stock Information Stock Quote & Chart Analyst Coverage Corporate Governance Governance Highlights Management Team Board of Directors Committee Composition Board Diversity Matrix Financials Quarterly Results Investor Resources FAQs Contact IR Email Alerts RSS Feeds Synlogic Announces Third Quarter 2020 Conference Call & Webcast Read more about Synlogic Announces Third Quarter 2020 Conference Call & Webcast Synlogic Presents Preclinical Data on SYNB8802 for Enteric Hyperoxaluria at American Society of Nephrology (ASN) Kidney Week 2020 Read more about Synlogic Presents Preclinical Data on SYNB8802 for Enteric Hyperoxaluria at American Society of Nephrology (ASN) Kidney Week 2020 Synlogic Appoints David Hava, Ph.D., as Chief Scientific Officer Read more about Synlogic Appoints David Hava, Ph.D., as Chief Scientific Officer Synlogic to Present at Upcoming Virtual Banking Conferences Read more about Synlogic to Present at Upcoming Virtual Banking Conferences Synlogic Reports Second Quarter 2020 Financial Results and Provides Business Update Read more about Synlogic Reports Second Quarter 2020 Financial Results and Provides Business Update Synlogic to Present at Upcoming Virtual Banking Conferences Read more about Synlogic to Present at Upcoming Virtual Banking Conferences Synlogic Announces Promotion of Antoine 'Tony' Awad to Chief Operating Officer and Additions to Leadership Team Read more about Synlogic Announces Promotion of Antoine 'Tony' Awad to Chief Operating Officer and Additions to Leadership Team Synlogic Announces Second Quarter 2020 Conference Call & Webcast Read more about Synlogic Announces Second Quarter 2020 Conference Call & Webcast Mike Burgess, MB, CHB, PHD Member of the Audit Committee Chair of the Science & Technology Committee Mike Burgess, MB, CHB, PHD Publication in Nature Communications Highlights the Preclinical Development of SYNB1891 and its Potential as a Dual Innate Immune Activator to Stimulate an Immune Response in Difficult to Treat Tumors Read more about Publication in Nature Communications Highlights the Preclinical Development of SYNB1891 and its Potential as a Dual Innate Immune Activator to Stimulate an Immune Response in Difficult to Treat Tumors Pagination First page « First Previous page ‹ Previous … Page 8 Page 9 Page 10 Page 11 Current page 12 Page 13 Page 14 Page 15 Page 16 … Next page Next › Last page Last » Subscribe to Investor Resources Contact IR Investor FAQs RSS Feeds Investor Email Alerts Email
Synlogic Announces Third Quarter 2020 Conference Call & Webcast Read more about Synlogic Announces Third Quarter 2020 Conference Call & Webcast
Synlogic Presents Preclinical Data on SYNB8802 for Enteric Hyperoxaluria at American Society of Nephrology (ASN) Kidney Week 2020 Read more about Synlogic Presents Preclinical Data on SYNB8802 for Enteric Hyperoxaluria at American Society of Nephrology (ASN) Kidney Week 2020
Synlogic Appoints David Hava, Ph.D., as Chief Scientific Officer Read more about Synlogic Appoints David Hava, Ph.D., as Chief Scientific Officer
Synlogic to Present at Upcoming Virtual Banking Conferences Read more about Synlogic to Present at Upcoming Virtual Banking Conferences
Synlogic Reports Second Quarter 2020 Financial Results and Provides Business Update Read more about Synlogic Reports Second Quarter 2020 Financial Results and Provides Business Update
Synlogic to Present at Upcoming Virtual Banking Conferences Read more about Synlogic to Present at Upcoming Virtual Banking Conferences
Synlogic Announces Promotion of Antoine 'Tony' Awad to Chief Operating Officer and Additions to Leadership Team Read more about Synlogic Announces Promotion of Antoine 'Tony' Awad to Chief Operating Officer and Additions to Leadership Team
Synlogic Announces Second Quarter 2020 Conference Call & Webcast Read more about Synlogic Announces Second Quarter 2020 Conference Call & Webcast
Mike Burgess, MB, CHB, PHD Member of the Audit Committee Chair of the Science & Technology Committee Mike Burgess, MB, CHB, PHD
Publication in Nature Communications Highlights the Preclinical Development of SYNB1891 and its Potential as a Dual Innate Immune Activator to Stimulate an Immune Response in Difficult to Treat Tumors Read more about Publication in Nature Communications Highlights the Preclinical Development of SYNB1891 and its Potential as a Dual Innate Immune Activator to Stimulate an Immune Response in Difficult to Treat Tumors